The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000774325
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
29/05/2026
Date registered
Help: Date registered
29/06/2026
Date last updated
Help: Date last updated
29/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
29/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Comparing single-channel cystometry with standard multi-channel urodynamic testing for detecting bladder function abnormalities in women undergoing urodynamics
Scientific title
Validity of single-channel cystometry compared with multi-channel cystometry for the diagnosis of urodynamic abnormalities in women undergoing clinically indicated urodynamic testing: a prospective cross-sectional diagnostic accuracy study
Additional trial identifiers [1] 317426 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
lower urinary tract symptoms 342104 0
urinary incontinence 342105 0
stress urinary incontinence 342106 0
overactive bladder 342107 0
Condition category
Condition code
Renal and Urogenital 338219 338219 0 0
Other renal and urogenital disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
What is the intervention: single-channel cystometry, performed as an additional diagnostic test after completion of clinically indicated standard multi-channel cystometry. Single-channel cystometry involves bladder filling with measurement of intravesical pressure only, without a separate abdominal/rectal pressure channel. It is used as the index test in this diagnostic accuracy study and will be compared with standard multi-channel cystometry, which is the reference standard.

Who delivers and their relevant expertise + how is it delivered: The procedure is delivered face to face, individually, during the participant’s routine urodynamic testing appointment at the participating clinical site. It is performed by urogynaecologists and gynaecologists along with urodynamics nursing staff who are trained and experienced in performing urodynamic testing in women with lower urinary tract symptoms.

How often, how long, where: Single-channel cystometry is performed once only for each participant, immediately after the standard multi-channel cystometry during the same appointment. The additional research procedure is expected to take approximately 5 minutes. It is conducted in the urodynamics clinic/procedure room using the same clinical environment and infection-control procedures as routine urodynamic testing.

Adherence: As this is a one-off diagnostic procedure performed during an attended clinic appointment, participant adherence strategies are not required. .
Intervention code [1] 334219 0
Diagnosis / Prognosis
Description of the comparator or control
No separate control group, individual patients act as their own control - This is a paired diagnostic accuracy study in which all participants undergo both the index test and the reference standard during the same clinical appointment.

The comparator/reference standard is clinically indicated standard multi-channel cystometry, performed as part of routine urodynamic testing. Multi-channel cystometry involves placement of a vesical/bladder pressure catheter transurethrally into the bladder, and an abdominal pressure catheter, usually placed transanal into rectum or into the vaginal. The pressure transducers connect to urodynamic equipment, allowing simultaneous recording of intravesical pressure and abdominal pressure, and calculation of detrusor pressure during bladder filling and provocation testing.

Single-channel cystometry is performed as an additional research index test after completion of standard multi-channel cystometry. For single-channel cystometry, the vesical and abdominal pressure sensor catheters used for multi-channel cystometry are removed. A single 12 Fr Foley's bladder catheter is used for bladder filling with sterile fluid. The catheter tubing is held vertically with the fluid meniscus approximately 15 cmH2O above the pubic symphysis, and the operator observes the fluid column during bladder filling. Unlike multi-channel cystometry, single-channel cystometry does not use a separate abdominal pressure channel, does not have pressure sensors, and does not produce a standard multi-channel pressure tracing.
Control group
Active

Outcomes
Primary outcome [1] 345585 0
Diagnostic accuracy of single-channel cystometry for detecting detrusor overactivity compared with multi-channel cystometry.
Timepoint [1] 345585 0
Assessed during the participant’s single urodynamic testing appointment, after completion of both standard multi-channel cystometry and the additional single-channel cystometry test.
Primary outcome [2] 345586 0
Diagnostic accuracy of single-channel cystometry for detecting urodynamic stress incontinence compared with multi-channel cystometry.
Timepoint [2] 345586 0
Assessed during the participant’s single urodynamic testing appointment, after completion of both standard multi-channel cystometry and the additional single-channel cystometry test.
Secondary outcome [1] 462266 0
Agreement between single-channel cystometry and multi-channel cystometry for first sensation volume.
Timepoint [1] 462266 0
Assessed during the participant’s single urodynamic testing appointment.
Secondary outcome [2] 462267 0
Agreement between single-channel cystometry and multi-channel cystometry for first desire volume.
Timepoint [2] 462267 0
Assessed during the participant’s single urodynamic testing appointment.
Secondary outcome [3] 462272 0
Agreement between single-channel cystometry and multi-channel cystometry for strong desire volume.
Timepoint [3] 462272 0
Assessed during the participant’s single urodynamic testing appointment.
Secondary outcome [4] 462273 0
Agreement between single-channel cystometry and multi-channel cystometry for maximum cystometric capacity.
Timepoint [4] 462273 0
Assessed during the participant’s single urodynamic testing appointment.
Secondary outcome [5] 462274 0
Meniscus movement (oscillation of fluid), or fluid expulsion from catheter on single-channel cystometry as composite outcome.
Timepoint [5] 462274 0
Assessed during the participant’s single urodynamic testing appointment.
Secondary outcome [6] 462275 0
Cough-provoked leak on single-channel cystometry.
Timepoint [6] 462275 0
Assessed during the participant’s single urodynamic testing appointment.
Secondary outcome [7] 462276 0
Adverse events related to urodynamic testing or the additional single-channel cystometry procedure.
Timepoint [7] 462276 0
Assessed during the participant’s urodynamic testing appointment, and for any delayed adverse events reported to the research or treating clinical team after the appointment.

Eligibility
Key inclusion criteria
Adult women aged 18 years or older referred for clinically indicated urodynamic testing in urogynaecology or urology practice.

Indications for urodynamic assessment may include stress urinary incontinence, urgency urinary incontinence or overactive bladder symptoms, mixed urinary incontinence, voiding dysfunction, pre-operative assessment before pelvic organ prolapse or continence surgery, or post-sling assessment.

Participants must be able and willing to provide written informed consent, able to tolerate standard urodynamic catheterisation and bladder filling procedures, and able to communicate bladder sensations and comply with study instructions, either in English or with interpreter assistance if required.
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Healthy volunteers
No
Key exclusion criteria
Active urinary tract infection at the time of testing.

Pregnancy.

Inability to tolerate urodynamic catheterisation or sequential bladder filling.

Inability to comply with instructions or communicate bladder sensations adequately for urodynamic assessment.

Inability to catheterise the bladder.

Visible haematuria requiring separate investigation.

Known or suspected urinary or genitourinary fistula.

Inability to undergo two sequential bladder fills during the same testing session.

Inability to provide informed consent.

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
The planned sample size is 200 participants. The sample size was based on a precision-based diagnostic accuracy calculation. The study aims to estimate the sensitivity and specificity of single-channel cystometry (SCC) compared with multi-channel cystometry (MCC) for detecting detrusor overactivity (DO) and urodynamic stress incontinence (USI), with a target absolute precision of approximately ±0.10 at the 95% confidence level. Assuming expected sensitivity and specificity of 0.80, approximately 62 MCC-positive and 62 MCC-negative cases are required for each target condition.

The total required evaluable sample size depends on the anticipated MCC-positive rate for each target condition. For DO, a conservative prevalence estimate of 38.9% was used for planning. At this prevalence, approximately 158–160 evaluable participants are required to obtain 62 MCC-positive DO cases. Allowing for a 10% non-evaluable rate gives an estimated requirement of approximately 176 recruited participants. The planned recruitment target has therefore been set at 200 participants to allow for technical failure, incomplete tests, indeterminate SCC findings, withdrawal, and attrition.

For USI, the expected MCC-positive rate is dependent on referral indication and on whether mixed USI plus DO cases are counted as USI-positive. In this study, USI and DO will be analysed as separate binary target conditions, and mixed USI plus DO cases will be counted as positive for each relevant endpoint. Assuming an MCC-defined USI positivity rate of approximately 40–60% in a clinically referred urodynamic population, the required evaluable sample size ranges from approximately 123 to 154 participants. This is lower than the conservative DO-driven requirement; therefore, the final sample size is based on the DO calculation.

Descriptive statistics will be used to summarise participant demographics, clinical characteristics, urodynamic indications, and baseline clinical variables. Continuous variables will be reported as mean and standard deviation or median and interquartile range depending on distribution. Categorical variables will be reported as frequencies and percentages.

Separate 2 × 2 diagnostic tables will be generated for DO and USI, comparing SCC findings with MCC findings. Sensitivity, specificity, positive predictive value, and negative predictive value will be calculated with 95% confidence intervals. Exact binomial confidence intervals will be used for diagnostic accuracy estimates. Agreement between SCC and MCC diagnoses will be assessed using Cohen’s kappa coefficient with 95% confidence intervals.

The primary analysis will be a complete-case analysis including participants with completed MCC and SCC results. Indeterminate SCC findings will be reported separately and excluded from the primary complete-case diagnostic accuracy analysis. Sensitivity analyses are planned in which indeterminate SCC results are alternatively classified as positive and negative to assess their effect on diagnostic accuracy estimates.

Agreement between SCC and MCC bladder sensation and capacity volumes will be assessed using paired analyses. Normally distributed continuous variables will be compared using paired t-tests; non-normally distributed variables will be compared using Wilcoxon signed-rank tests. Agreement between continuous measures will be assessed using Bland–Altman analysis and intraclass correlation coefficients where appropriate.

Exploratory analyses will examine whether specific SCC features, including meniscus movement or expulsion and cough-provoked leak, predict MCC-defined DO or USI. This SCC feature will be evaluated as a predictor of MCC-defined DO using logistic regression where event numbers are sufficient, with odds ratios and 95% confidence intervals reported where appropriate. Model performance will be assessed using area under the receiver operating characteristic curve where appropriate.

No imputation is planned for missing data. Reasons for missing, incomplete, technically failed, or indeterminate tests will be tabulated. If missing data exceed 5% for primary outcomes, sensitivity analyses will be performed to assess the robustness of findings. Diagnostic accuracy estimates will be interpreted primarily by point estimates and confidence intervals rather than hypothesis testing.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 29559 0
Greenslopes Private Hospital - Greenslopes
Recruitment hospital [2] 29731 0
Goldfields Specialists - Bendigo
Recruitment postcode(s) [1] 45882 0
4120 - Greenslopes
Recruitment postcode(s) [2] 46077 0
3550 - Bendigo

Funding & Sponsors
Funding source category [1] 322003 0
Self funded/Unfunded
Name [1] 322003 0
Investigator-initiated unfunded study
Country [1] 322003 0
Funding source category [2] 322083 0
Hospital
Name [2] 322083 0
Greenslopes Private Hospital
Country [2] 322083 0
Australia
Primary sponsor type
Individual
Name
Dr Hnin Yee Kyaw, Griffith University School of Medicine / Gold Coast University Hospital
Address
Country
Australia
Secondary sponsor category [1] 324879 0
None
Name [1] 324879 0
Address [1] 324879 0
Country [1] 324879 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320535 0
Ramsay Health Care Human Research Ethics Committee A
Ethics committee address [1] 320535 0
Ethics committee country [1] 320535 0
Australia
Date submitted for ethics approval [1] 320535 0
Approval date [1] 320535 0
19/05/2026
Ethics approval number [1] 320535 0
2025/ETH/0107

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150786 0
Dr Hnin Yee Kyaw
Address 150786 0
Ramsay Specialist Centre, Suite 209, Level/2 Newdegate St, Greenslopes QLD 4120
Country 150786 0
Australia
Phone 150786 0
+61738479909
Fax 150786 0
Email 150786 0
Contact person for public queries
Name 150787 0
Hnin Yee Kyaw
Address 150787 0
Ramsay Specialist Centre, Suite 209, Level/2 Newdegate St, Greenslopes QLD 4120
Country 150787 0
Australia
Phone 150787 0
+61738479909
Fax 150787 0
Email 150787 0
Contact person for scientific queries
Name 150788 0
Hnin Yee Kyaw
Address 150788 0
Ramsay Specialist Centre, Suite 209, Level/2 Newdegate St, Greenslopes QLD 4120
Country 150788 0
Australia
Phone 150788 0
+61738479909
Fax 150788 0
Email 150788 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Individual participant data will not be made publicly available. The study involves collection of personal and health information from women undergoing urodynamic testing, and participant consent has been obtained for use of data for this specific research project only. Data will be stored securely, used for the approved study purposes, and reported only in aggregated, non-identifiable form. De-identified data may be shared between participating Australian study sites for pooled analysis under formal data-sharing arrangements, but raw line-by-line individual participant data will not be publicly released.




What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.